Basics Brainstorm Cell Therapeutics Inc. Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company develops novel adult stem cell therapies for debilitating neurodegenerative disorders such as ALS, MS, and PD among others. IPO Date: November 1, 2003 Sector: Healthcare Industry: Biotech Market Cap: $7.57M Activated in VL: True Average Daily Range Avg Daily Range: $0.11 | 3.44% Avg Daily Range (30 D): $0.07 | 6.09% Avg Daily Range (90 D): $0.06 | 4.27% Institutional Daily Volume Avg Daily Volume: .34M Avg Daily Volume (30 D): .19M Avg Daily Volume (90 D): .09M Trade Size Avg Trade Size (Sh.): 281 Avg Trade Size (Sh.) (30 D): 272 Avg Trade Size (Sh.) (90 D): 250 Institutional Trades Total Inst.Trades: 20 Avg Inst. Trade: $1.67M Avg Inst. Trade (30 D): $.62M Avg Inst. Trade (90 D): $.62M Avg Inst. Trade Volume: .04M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $3.27M Avg Closing Trade (30 D): $M Avg Closing Trade (90 D): $M Avg Closing Volume: 53.4K         News May 6, 2025 @ 11:00 AM BrainStorm to Present Biomarker Insights Supportin... Source: Prnewswire Mar 26, 2025 @ 12:15 PM BrainStorm Cell Therapeutics Granted Compliance Ex... Source: Prnewswire Feb 21, 2025 @ 6:00 PM Cell and Gene Therapies in Rare Disorders Market t... Source: Delveinsight Apr 9, 2024 @ 10:05 AM Why Biophytis Shares Are Trading Higher By Around ... Source: Avi Kapoor Mar 25, 2024 @ 6:44 PM Why Landos Biopharma Shares Are Trading Higher By ... Source: Avi Kapoor Financials   TTM Q4 2024 FY 2024 Basic EPS $-2.31 $-.51 $-2.31 Diluted EPS $-2.31 $-.51 $-2.31 Revenue $ $ $ Gross Profit $ $ $ Net Income / Loss $ -11.62M $ -2.97M $ -11.62M Operating Income / Loss $ -11.69M $ -3.19M $ -11.69M Cost of Revenue $ $ $ Net Cash Flow $ -1.11M $ -1.11M $ -1.11M PE Ratio     Splits Oct 01, 2024:   15:1 Sep 16, 2014:   15:1 Aug 13, 2003:   1:2